No data available.
Please log in to see this content.
You have no subscription access to this content.
No metrics data to plot.
The attempt to load metrics for this article has failed.
The attempt to plot a graph for these metrics has failed.
Ototoxicity risk assessment combining distortion product otoacoustic emissions with a cisplatin dose modela)
1.Alam, S. , Ikeda, K. , Oshima, T. , Suzuki, M. , Kawase, T. , Kikuchi, T. , and Takasaka, T. (2000). “Cisplatin-induced apoptotic cell death in Mongolian gerbil cochlea,” Hear. Res. 141, 28–38.
2.Amalraj, S. , Starkweather, C. , Nguyen, C. , and Naeim, A. (2009). “Health literacy, communication, and treatment decision-making in older cancer patients,” Oncology 23, 369–375.
3.Arnold, D. , Lonsbury-Martin, B. , and Martin, G. (1999). “High-frequency hearing influences lower-frequency distortion-product otoacoustic emissions,” Arch. Otolaryngol. Head Neck Surg. 125, 215–222.
4.ASHA (1994). “Guidelines for the audiologic management of individuals receiving cochleotoxic drug therapy,” American Speech-Language-Hearing Association, www.ashaorg/docs/html/GL1994-00003.html, pp. 11–19.
7.Carhart, R. , and Jerger, J. (1959). “Preferred method for clinical determination of pure-tone thresholds,” J. Speech Hear Disord. 24, 330–345.
8.Dalton, D. , Cruickshanks, K. , Klein, B. , Klein, R. , Wiley, T. , and Nondahl, D. (2003). “The impact of hearing loss on quality of life in older adults,” Gerontologist 43, 661–668.
9.Deeter, R. , Abel, R. , Calandruccio, L. , and Dhar, S. (2009). “Contralateral acoustic stimulation alters the magnitude and phase of distortion product otoacoustic emissions,” J. Acoust. Soc. Am. 126, 2413–2424.
10.Dorn, P. , Piskorski, P. , Gorga, M. , Neely, S. , and Keefe, D. (1999). “Predicting audiometric status from distortion product otoacoustic emissions using multivariate analysis,” Ear Hear. 20, 149–163.
11.Durrant, J. , Palmer, C. , and Lunner, T. (2005). “Analysis of counted behaviors in a single-subject design: Modeling of hearing-aid intervention in hearing-aid patients with Alzheimer’s disease,” Int. J. Audiol. 44, 31–38.
12.Fausti, S. , Frey, R. , Erickson, D. , Rappaport, B. , Cleary, E. , and Brummert, R. (1979). “A system for evaluating auditory function from 8,000–20,000 Hz,” J. Acoust. Soc. Am. 66, 1713–1718.
13.Fausti, S. , Frey, R. , Henry, J. , Olson, D. , and Schaffer, H. (1992). “Early detection of ototoxicity using high-frequency, tone-burst-evoked auditory brainstem responses,” J. Am. Acad. Audiol 3, 397–404.
14.Fausti, S. , Rappaport, B. , Frey, R. , Henry, J. , Phillips, D. , Mitchell, C. , and Olson, D. (1991). “Reliability of evoked responses to high-frequency (8–14 kHz) tone bursts,” J. Am. Acad. Audiol 2, 105–114.
15.Fischel-Ghodsian, N. , Prezant, T. , Bu, X. , and Oztas, S. (1993). “Mitochondrial ribosomal RNA gene mutation in a patient with sporadic aminoglycoside ototoxicity,” Am. J. Otolaryngol. 14, 399–403.
16.Fitzmaurice, G. , Laird, N. , and Ware, J. (2004). Applied Longitudinal Analysis (Wiley, Hoboken, NJ), pp. 291–321.
19.Gorga, M. , Neely, S. , and Dorn, P. (1999). “Distortion product otoacoustic emission test performance for a priori criteria and for multifrequency audiometric standards,” Ear Hear. 20, 345–362.
20.Gorga, M. , Neely, S. , Ohlrich, B. , Redner, J. , and Peters, J. (1997). “From laboratory to clinic: A large scale study of distortion product otoacoustic emissions in ears with normal hearing and ears with hearing loss,” Ear Hear. 18, 440–455.
21.Gorga, M. , Stover, L. , Neely, S. , and Montoya, D. (1996). “The use of cumulative distributions to determine critical values and levels of confidence for clinical distortion product otoacoustic emission measurements,” J. Acoust. Soc. Am. 100, 968–977.
22.Hanley, J. , and McNeil, B. (1982). “The meaning and use of the area under a receiver operating characteristic (ROC) curve,” Radiology 143, 29–36.
23.Harding, G. , and Bohne, B. (2004). “Temporary DPOAE level shifts, ABR threshold shifts and histopathological damage following below-critical-level noise exposure,” Hear. Res. 196, 94–108.
24.Hastie, T. , Tibshirani, R. , and Friedman, J. (2009). The Elements of Statistical Learning: Data Mining, Inference and Prediction (Springer, New York), pp. 241–245.
25.Hodges, A. , and Lonsbury-Martin, B. (1998). Hearing Management (Singular, San Diego), pp. 269–290.
26.Howard, M. , Stagner, B. , Lonsbury-Martin, B. , and Martin, G. (2002). “Effects of reversible noise exposure on the suppression tuning of rabbit distortion-product otoacoustic emissions,” J. Acoust. Soc. Am. 111, 285–296.
27.Knight, K. , Kraemer, D. , Winter, C. , and Neuwelt, E. (2007). “Early changes in auditory function as a result of platinum chemotherapy: Use of extended high-frequency audiometry and evoked distortion product otoacoustic emissions,” J. Clin. Oncol. 25, 1190–1195.
28.Kochkin, S. , and Rogin, C. (2000). “Quantifying the obvious: The impact of hearing instruments on the quality of life,” Hear. Rev. 7, 6–34.
29.Laurell, G. , Viberg, A. , Teixeira, M. , Sterkers, O. , and Ferrary, E. (2000). “Blood-perilymph barrier and ototoxicity: An in vivo study in the rat,” Acta Oto-Laryngol. 120, 796–803.
30.Martin, G. , Stagner, B. , Fahey, P. , and Lonsbury-Martin, B. (2009). “Steep and shallow phase gradient distortion product otoacoustic emissions arising basal to the primary tones,” J. Acoust. Soc. Am. 125, EL85–EL92.
31.Mauermann, M. , and Kollmeier, B. (2004). “Distortion product otoacoustic emissions (DPOAE) input/output functions and the influence of the second DPOAE source,” J. Acoust. Soc. Am. 116, 2199–2212.
33.Mukherjea, D. , Whitworth, C. , Nandish, S. , Dunaway, G. , Rybak, L. , and Ramkumar, V. (2006). “Expression of the kidney infury molecule 1 in the rat cochlea and induction by cisplatin,” Neuroscience 139, 733–740.
34.Neely, S. , and Liu, Z. (1994). EMAV: Otoacoustic Emission Averager (Boys Town National Research Hospital, Omaha, NE).
37.Reavis, K. , McMillan, G. , Austin, D. , Fausti, S. , and Konrad-Martin, D. (2010). “Distortion-product otoacoustic emission test performance for ototoxicity monitoring,” Ear Hear. In press.
38.Reavis, K. M. , Phillips, D. S. , Fausti, S. J. , Gordon, J. S. , Helt, W. J. , Willington, D. , Bratt, G. W. , and Konrad-Martin, D. (2008). “Factors affecting sensitivity of distortion-product otoacoustic emissions to ototoxic hearing loss,” Ear Hear. 29, 875–893.
39.Ress, B. D. , Sridhar, K. S. , Balkany, T. J. , Waxman, G. M. , Stagner, B. B. , and Lonsbury-Martin, B. L. (1999). “Effects of cis-platin chemotherapy on otoacoustic emissions: The development of an objective screening protocol,” Otolaryngol.-Head Neck Surg. 121, 693–701.
40.Roede, J. , Harris, F. , Probst, R. , and Xu, L. (1993). “Repeatability of distortion product otoacoustic emissions in normally hearing humans,” Audiology 32, 273–281.
41.Shera, C. , and Guinan, J. (1999). “Evoked otoacoustic emissions arise by two fundamentally different mechanisms: A taxonomy for mammalian OAEs,” J. Acoust. Soc. Am. 105, 782–798.
43.Stavroulaki, P. , Vossinakis, I. , Dinopoulou, D. , Doudounakis, S. , Adamopoulos, G. , and Apostolopoulos, N. (2002). “Otoacoustic emissions for monitoring aminoglycoside-induced ototoxicity in children with cystic fibrosis,” Arch. Otolaryngol. Head Neck Surg. 128, 150–155.
44.Sutton, L. A. , Lonsbury-Martin, B. L. , Martin, G. K. , and Whitehead, M. L. (1994). Sensitivity of distortion-product otoacoustic emissions in humans to tonal over-exposure: Time course of recovery and effects of lowering L2,” Hear. Res. 75 1–2, 161–174.
Article metrics loading...
Full text loading...
Most read this month